• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Commentarynobel prize

The secret Chinese operation that conquered malaria — and won a Nobel

By
Jia-Chen Fu
Jia-Chen Fu
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
By
Jia-Chen Fu
Jia-Chen Fu
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
October 7, 2015, 9:51 AM ET
(FOCUS)SWEDEN-NOBEL PRIZE-CHINA-TU YOUYOU (CN)
BEIJING, Oct. 5, 2015-- Undated file photo shows Tu Youyou, right front, a pharmacologist with the China Academy of Chinese Medical Sciences, working with professor Lou Zhicen to study the traditional Chinese medicine, in 1950s. China's Tu Youyou, Irish-born William Campbell, and Japan's Satoshi Omura jointly won the 2015 Nobel Prize for Physiology or Medicine, the Nobel Assembly at Sweden's Karolinska Institute announced on Monday. Tu won half of the prize for her discoveries concerning a novel therapy against malaria. (Xinhua via Getty Images)Photograph by Xinhua News Agency/Getty Images

At the height of the Cultural Revolution, Project 523 — a covert operation launched by the Chinese government and headed by a young Chinese medical researcher by the name of Tu Youyou — discovered what has been the most powerful and effective antimalarial drug therapy to date.

Known in Chinese as qinghaosu and derived from the sweet wormwood (Artemisia annua L.), artemisinin was only one of several hundred substances Tu and her team of researchers culled from Chinese drugs and folk remedies and systematically tested in their search for a treatment to chloroquine-resistant malaria.

How Tu and her team discovered artemisinin tells us much about the continual Chinese effort to negotiate between traditional/modern and indigenous/foreign.

Indeed, contrary to popular assumptions that Maoist China was summarily against science and scientists, the Communist party-state needed the scientific elite for certain political and practical purposes.

Medicine, particularly when it also involved foreign relations, was one such area. In this case, it was the war in Vietnam and the scourge of malaria that led to the organization of Project 523.

A request from Vietnam and a military answer

As fighting escalated between American and Vietnamese forces throughout the 1960s, malaria became the number one affliction compromising Vietnamese soldier health. The increasing number of chloroquine-resistant malaria cases in the civilian population further heightened North Vietnamese concern.

In 1964, the North Vietnamese government approached Chinese leader Mao Tse Tung and asked for Chinese assistance in combating malaria. Mao responded, “Solving your problem is the same as solving our own.”

From the beginning, Project 523, which was classified as a top-secret state mission, was under the direction of military authorities. Although civilian agencies were invited to collaborate in May 1967, military supervision highlighted the urgent nature of the research and protected it from adverse political winds.

The original three-year plan produced by the People’s Liberation Army Research Institute aimed to “integrate far and near, integrate Chinese and Western medicines, take Chinese drugs as its priority, emphasize innovation, unify plans, divide labor to work together.”

The medical mission

Project 523 had three goals: the identification of new drug treatments for fighting chloroquine-resistant malaria, the development of long-term preventative measures against chloroquine-resistant malaria, and the development of mosquito repellents.

To achieve these ends, research on Chinese drugs and acupuncture was integral.

The decision to investigate Chinese drugs was not without precedent. Back in 1926, Chen Kehui and Carl Schmidt of the Peking Union Medical College published their original paper on ephedrine, derived from Chinese herb mahuang. It ignited a research fire in which more than 500 scientific papers on ephedrine (for relief for asthma) appeared around the world by 1929.

In the 1940s, state interest in the Chinese drug changshan and its antimalarial properties led to the establishment of a state-funded research institute and experimental farm in Sichuan province.

Project 523’s embrace of Chinese materia medica — the traditional body of knowledge about substances’ healing properties — is a more recent example of the efforts to “scientize” Chinese medicine through selective appropriation and detailed investigation.

Biomedical interest in Chinese drugs was not in itself new. But the institutional climate within which Project 523 investigators worked was different from earlier antimalarial research efforts. The Vietnam War had exacerbated an epidemiological crisis to which Maoist China responded with nationalist fervor by turning to its institutions of traditional Chinese medicine.

In the 1960s, such institutions were a mixing ground of specialists, many of whom possessed more than a passing familiarity with Chinese medicine and biomedicine. This ensured that qinghao research proceeded within a climate in which scientists, “who themselves had learnt the ways of appreciating traditional knowledge, worked side by side with historians of traditional medicine, who had textual learning.”

Tu Youyou’s story

Tu Youyou’s research fits within this Maoist story of medical systematization and standardization.

Born in 1930, she was a medical student during the 1950s, when state efforts to make Chinese medicine scientific through the research and expertise of biomedical researchers were especially acute. She rose to the head of a malaria research group at the Beijing Academy of Traditional Chinese Medicine in 1969.

The group was composed of phytochemical researchers who studied the chemical compounds that occur naturally in plants and pharmacological researchers who focused on the science of drugs. They began with a list of over 2,000 Chinese herbal preparations, of which 640 preparations were found to have possible antimalarial activities. They worked steadily and obtained more than 380 extracts from some 200 Chinese herbs, which they then evaluated against a mouse model of malaria.

Of the 380-plus extracts they had obtained, a qinghao (Artemisia annua L.) extract appeared promising, but inconsistently so. Faced with varying results, Tu and her team returned to the existing materia medica literature and reexamined each instance in which qinghao appeared in a traditional recipe.

Tu was drawn to one particular reference made by Ge Hong 葛洪 (284-363) in his fourth-century BC text, Emergency Prescriptions One Keeps Up One’s Sleeve. Ge Hong instructed: “Take a bunch of qing hao and two sheng [2 x 0.2 liter] of water for soaking it, wring it out to obtain the juice, and ingest it in its entirety.”

In what can be characterized as her eureka moment, Tu had the idea that “the heating involved in the conventional extraction step we had used might have destroyed the active components, and that extraction at a lower temperature might be necessary to preserve antimalarial activity.” Her hunch proved correct: Once they switched to a lower-temperature procedure, Tu and her team obtained much better and more consistent antimalarial activity with qinghao. By 1971, they had obtained a nontoxic and neutral extract that was called qinghaosu or artemisinin. It was 100% effective against malarial parasites in animal models.

Tu’s research has drawn accolades from the international scientific community, while also igniting a debate in the Chinese language media about the celebration of individual inventors over collective group efforts.

This too, perhaps, may be part of the legacy of Maoist mass science, which demanded research that served practical needs and engaged the masses. Scientific achievement, while important, was not the be-all, end-all of scientific work. During the Cultural Revolution, it mattered that science proceed along revolutionary lines. It mattered that scientific advances resulted from collective endeavor and drew from popular sources. Does it still?

Jia-Chen Fu is an assistant professor of Chinese at Emory University. This article originally appeared on The Conversation.

The Conversation

About the Authors
By Jia-Chen Fu
See full bioRight Arrow Button Icon
By Bethany Cianciolo
See full bioRight Arrow Button Icon

Latest in Commentary

Alex Amouyel is the President and CEO of Newman’s Own Foundation
Commentaryphilanthropy
Following in Paul Newman and Yvon Chouinard’s footsteps: There are more ways for leaders to give it away in ‘the Great Boomer Fire Sale’ than ever
By Alex AmouyelDecember 7, 2025
18 hours ago
Amit Walia
CommentaryM&A
Why the timing was right for Salesforce’s $8 billion acquisition of Informatica — and for the opportunities ahead
By Amit WaliaDecember 6, 2025
2 days ago
Steve Milton is the CEO of Chain, a culinary-led pop-culture experience company founded by B.J. Novak and backed by Studio Ramsay Global.
CommentaryFood and drink
Affordability isn’t enough. Fast-casual restaurants need a fandom-first approach
By Steve MiltonDecember 5, 2025
3 days ago
Paul Atkins
CommentaryCorporate Governance
Turning public companies into private companies: the SEC’s retreat from transparency and accountability
By Andrew BeharDecember 5, 2025
3 days ago
Matt Rogers
CommentaryInfrastructure
I built the first iPhone with Steve Jobs. The AI industry is at risk of repeating an early smartphone mistake
By Matt RogersDecember 4, 2025
4 days ago
Jerome Powell
CommentaryFederal Reserve
Fed officials like the mystique of being seen as financial technocrats, but it’s time to demystify the central bank
By Alexander William SalterDecember 4, 2025
4 days ago

Most Popular

placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
1 day ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
1 day ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
3 days ago
placeholder alt text
Politics
Supreme Court to reconsider a 90-year-old unanimous ruling that limits presidential power on removing heads of independent agencies
By Mark Sherman and The Associated PressDecember 7, 2025
16 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.